Literature DB >> 31007176

Animal models for hepatocellular carcinoma.

Hui Emma Zhang1, James M Henderson1, Mark D Gorrell2.   

Abstract

Hepatocellular carcinoma (HCC) represents ~90% of all cases of primary liver cancer and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. Establishing appropriate animal models for HCC is required for basic and translational studies, especially the models that can recapitulate one of the human disease settings. Current animal models can be categorized as chemically-induced, genetically-engineered, xenograft, or a combination of these with each other or with a metabolic insult. A single approach to resemble human HCC in animals is not sufficient. Combining pathogenic insults in animal models may more realistically recapitulate the multiple etiologic agents occurring in humans. Combining chemical injury with metabolic disorder or alcohol consumption in mice reduces the time taken to hepatocarcinogenesis. Genetically-engineering weak activation of HCC-promoting pathways combined with disease-specific injury models will possibly mimic the pathophysiology of human HCC in distinct clinical settings.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Animal model; Chemical; Genetically engineered mouse; Hepatocellular carcinoma; Xenograft

Mesh:

Substances:

Year:  2018        PMID: 31007176     DOI: 10.1016/j.bbadis.2018.08.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  8 in total

1.  New Approach about the Signaling Crosstalk between IQGAPs/ NF- κB/IL-8 and PDCD5/p53/TRAIL Pathways that Modulate Malignant Transformation in Hepatocellular Carcinoma.

Authors:  Khairy M A Zoheir; Mohamed A Abdelhafez; Ahmed M Darwish; Karima F Mahrous
Journal:  Asian Pac J Cancer Prev       Date:  2022-01-01

Review 2.  Mouse Models for Immunotherapy in Hepatocellular Carcinoma.

Authors:  Enya Li; Li Lin; Chia-Wei Chen; Da-Liang Ou
Journal:  Cancers (Basel)       Date:  2019-11-15       Impact factor: 6.639

Review 3.  Current Challenges in Image-Guided Magnetic Hyperthermia Therapy for Liver Cancer.

Authors:  Anirudh Sharma; Erik Cressman; Anilchandra Attaluri; Dara L Kraitchman; Robert Ivkov
Journal:  Nanomaterials (Basel)       Date:  2022-08-12       Impact factor: 5.719

4.  In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions.

Authors:  Clara T Nicolas; Caitlin J VanLith; Raymond D Hickey; Zeji Du; Lori G Hillin; Rebekah M Guthman; William J Cao; Benjamin Haugo; Annika Lillegard; Diya Roy; Aditya Bhagwate; Daniel O'Brien; Jean-Pierre Kocher; Robert A Kaiser; Stephen J Russell; Joseph B Lillegard
Journal:  Nat Commun       Date:  2022-08-25       Impact factor: 17.694

5.  Inhibition of anti-inflammatory pathway through suppressors of cytokine signalling (Socs2/Socs3) in the initiation of hepatocellular carcinoma.

Authors:  Isbah Ashfaq; Nadeem Sheikh; Naz Fatima; Asima Tayyeb
Journal:  Saudi J Biol Sci       Date:  2022-06-20       Impact factor: 4.052

6.  Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.

Authors:  Mahmoud Ma Elsayed; Mahmoud E Mostafa; Eman Alaaeldin; Hatem Aa Sarhan; Montaser ShA Shaykoon; Shady Allam; Ahmed Rh Ahmed; Bakheet Em Elsadek
Journal:  Int J Nanomedicine       Date:  2019-10-29

7.  Cirrhotic Human Liver Extracellular Matrix 3D Scaffolds Promote Smad-Dependent TGF-β1 Epithelial Mesenchymal Transition.

Authors:  Giuseppe Mazza; Andrea Telese; Walid Al-Akkad; Luca Frenguelli; Ana Levi; Martina Marrali; Lisa Longato; Kessarin Thanapirom; Maria Giovanna Vilia; Benedetta Lombardi; Claire Crowley; Mark Crawford; Morten A Karsdal; Diana J Leeming; Giusi Marrone; Katrin Bottcher; Benjamin Robinson; Armando Del Rio Hernandez; Domenico Tamburrino; Gabriele Spoletini; Massimo Malago; Andrew R Hall; Jasminka Godovac-Zimmermann; Tu Vinh Luong; Paolo De Coppi; Massimo Pinzani; Krista Rombouts
Journal:  Cells       Date:  2019-12-28       Impact factor: 6.600

Review 8.  Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention.

Authors:  Danny Orabi; Nathan A Berger; J Mark Brown
Journal:  Cancers (Basel)       Date:  2021-07-11       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.